according to a poster presented at the Pulmonary Vascular Research Institute 2025 Annual Congress. In this series, we dive into what rheumatologists should know about pulmonary hypertension ...

A recent publication in the International Journal of Cardiology, "Pulmonary artery denervation in pulmonary hypertension: A ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

At the root of ARDS is the host vascular response (HVR), an inflammatory ... such as global pandemics and other emerging infectious-disease threats. “Funding from the US Department of Defense ...

release inflammatory factors that cause vascular disease to progress. They further showed that other macrophage subtypes ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...